S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)

By sjmartinez • May 2, 2025

Saeed A, Colby S, Oberstein PE, Duda DG, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha FG, Senthil M, Safyan RA, Wainberg ZA, Iqbal S, Chiorean EG, Philip PA. S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncol. 2025 May;21(11):1325-1331. doi: 10.1080/14796694.2025.2485020. Epub 2025 Mar 28. PMID: 40155326.

Tags: anti-programmed death-1, combined positive score, esophageal cancer, gastric, gastroesophageal junction, Hematology/Oncology, immunotherapy, paclitaxel, Publications, ramucirumab, vascular endothelial growth factor

Vanishing Bile Duct Syndrome as a Rare Complication of Classic Hodgkin’s Lymphoma: A Case Report and Literature Review

Tai JW, Shah VD, Harmon RL, Chandna S, Yan J, Fathizadeh P, Beaven S, Karunasiri D, Kim P. Vanishing Bile Duct Syndrome as a Rare[...]

Targeting TIGIT to improve outcomes in advanced HCC

Bejjani AC, Roayaie S, Finn RS. Targeting TIGIT to improve outcomes in advanced HCC. JHEP Rep. 2025 Oct 9;7(11):101552. doi: 10.1016/j.jhepr.2025.101552. PMID: 41635625; PMCID: PMC12861928.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report

Zeidner JF, Jain J, Welkie RL, Huang Y, Swords R, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH Jr, Baer MR, Duong VH,[...]